These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 36032092)

  • 1. Immunogenicity and toxicity of AAV gene therapy.
    Ertl HCJ
    Front Immunol; 2022; 13():975803. PubMed ID: 36032092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical models to assess the immunogenicity of AAV vectors.
    Ertl HCJ
    Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T Cell-Mediated Immune Responses to AAV and AAV Vectors.
    Ertl HCJ
    Front Immunol; 2021; 12():666666. PubMed ID: 33927727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy.
    Ertl HCJ; High KA
    Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
    Mays LE; Wilson JM
    Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
    Rapti K; Grimm D
    Front Immunol; 2021; 12():753467. PubMed ID: 34777364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
    Vandamme C; Adjali O; Mingozzi F
    Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory and Exhausted T Cell Responses to AAV Capsid.
    Gernoux G; Wilson JM; Mueller C
    Hum Gene Ther; 2017 Apr; 28(4):338-349. PubMed ID: 28323492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.
    Hamilton BA; Wright JF
    Front Immunol; 2021; 12():675897. PubMed ID: 34084173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of CpG Sequences on Capsid-Specific CD8
    Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
    Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
    Verdera HC; Kuranda K; Mingozzi F
    Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CpG Depletion of Vector Genome on CD8
    Bertolini TB; Shirley JL; Zolotukhin I; Li X; Kaisho T; Xiao W; Kumar SRP; Herzog RW
    Front Immunol; 2021; 12():672449. PubMed ID: 34135899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
    Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
    Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to adeno-associated virus vectors.
    Zaiss AK; Muruve DA
    Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG-depleted adeno-associated virus vectors evade immune detection.
    Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
    J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
    Mingozzi F; High KA
    Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
    Zhu J; Huang X; Yang Y
    J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.